NCT04532645Completed
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting
Source: ClinicalTrials.gov · Last updated 23 Sept 2025
Brief summary (registry, in English)
This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 342 (actual)
- First submitted
- 26 Aug 2020
- Start date
- 7 Jan 2021
- Primary completion date
- 27 Sept 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Ovarian cancer
- NCT number
- NCT04532645
What you commit to
- Study type: Observational
- Participants enrolled: 342
- From 7 Jan 2021 to the primary completion date, 27 Sept 2024
- 49 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in any clinical study with an investigational product at the time of olaparib initiation
Other
- Withdrawal of informed consent (where consent required)
Who the study is looking for
- Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III - IV) epithelial ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer who have completed first line platinum-based chemotherapy, in PR/CR and treated with at least one dose of olaparib in first line maintenance setting
- Patients aged ≥18 years old
- Ability and/or willingness to provide a signed informed consent form (where required)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (49)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.